These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1205 related articles for article (PubMed ID: 27465508)

  • 21. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia.
    Moshaver B; van Rhenen A; Kelder A; van der Pol M; Terwijn M; Bachas C; Westra AH; Ossenkoppele GJ; Zweegman S; Schuurhuis GJ
    Stem Cells; 2008 Dec; 26(12):3059-67. PubMed ID: 19096043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication.
    Rickmann M; Krauter J; Stamer K; Heuser M; Salguero G; Mischak-Weissinger E; Ganser A; Stripecke R
    Ann Hematol; 2011 Sep; 90(9):1047-58. PubMed ID: 21520003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117.
    Haase D; Feuring-Buske M; Schäfer C; Schoch C; Troff C; Gahn B; Hiddemann W; Wörmann B
    Leukemia; 1997 May; 11(5):674-9. PubMed ID: 9180291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of FLT3-ITD
    Travaglini S; Angelini DF; Alfonso V; Guerrera G; Lavorgna S; Divona M; Nardozza AM; Consalvo MI; Fabiani E; De Bardi M; Neri B; Forghieri F; Marchesi F; Paterno G; Cerretti R; Barragan E; Fiori V; Dominici S; Del Principe MI; Venditti A; Battistini L; Arcese W; Lo-Coco F; Voso MT; Ottone T
    Blood Cancer J; 2020 Aug; 10(8):85. PubMed ID: 32843624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enrichment of N-Cadherin and Tie2-bearing CD34+/CD38-/CD123+ leukemic stem cells by chemotherapy-resistance.
    Zhi L; Wang M; Rao Q; Yu F; Mi Y; Wang J
    Cancer Lett; 2010 Oct; 296(1):65-73. PubMed ID: 20444543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FLT3-ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression.
    Soare DS; Radu E; Dumitru I; Popov VM; Bumbea H; Vlădăreanu AM
    J Cell Mol Med; 2020 Jul; 24(13):7675-7679. PubMed ID: 32460405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.
    Yoshimoto G; Miyamoto T; Jabbarzadeh-Tabrizi S; Iino T; Rocnik JL; Kikushige Y; Mori Y; Shima T; Iwasaki H; Takenaka K; Nagafuji K; Mizuno S; Niiro H; Gilliland GD; Akashi K
    Blood; 2009 Dec; 114(24):5034-43. PubMed ID: 19808698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML.
    Zhang B; Nguyen LXT; Zhao D; Frankhouser DE; Wang H; Hoang DH; Qiao J; Abundis C; Brehove M; Su YL; Feng Y; Stein A; Ghoda L; Dorrance A; Perrotti D; Chen Z; Han A; Pichiorri F; Jin J; Jovanovic-Talisman T; Caligiuri MA; Kuo CJ; Yoshimura A; Li L; Rockne RC; Kortylewski M; Zheng Y; Carlesso N; Kuo YH; Marcucci G
    J Hematol Oncol; 2021 Aug; 14(1):122. PubMed ID: 34372909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
    Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
    Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FLT3 Internal Tandem Duplication Mutation, cMPL and CD34 Expressions Predict Low Survival in Acute Myeloid Leukemia Patients.
    Ebrahim EK; Assem MM; Amin AI; Kamel MM; El Meligui YM; Metwally AM
    Ann Clin Lab Sci; 2016 Dec; 46(6):592-600. PubMed ID: 27993871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment.
    Mony U; Jawad M; Seedhouse C; Russell N; Pallis M
    Leukemia; 2008 Jul; 22(7):1395-401. PubMed ID: 18509353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.
    Xie LH; Biondo M; Busfield SJ; Arruda A; Yang X; Vairo G; Minden MD
    Blood Cancer J; 2017 Jun; 7(6):e567. PubMed ID: 28574487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
    Zhang L; Zhou Y; Chen K; Shi P; Li Y; Deng M; Jiang Z; Wang X; Li P; Xu B
    Target Oncol; 2017 Oct; 12(5):677-687. PubMed ID: 28710745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
    Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
    Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia.
    Chávez-González A; Dorantes-Acosta E; Moreno-Lorenzana D; Alvarado-Moreno A; Arriaga-Pizano L; Mayani H
    Arch Med Res; 2014 May; 45(4):343-50. PubMed ID: 24751333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia.
    Hwang K; Park CJ; Jang S; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH; Im HJ; Seo JJ
    Ann Hematol; 2012 Oct; 91(10):1541-6. PubMed ID: 22669506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.
    Vergez F; Green AS; Tamburini J; Sarry JE; Gaillard B; Cornillet-Lefebvre P; Pannetier M; Neyret A; Chapuis N; Ifrah N; Dreyfus F; Manenti S; Demur C; Delabesse E; Lacombe C; Mayeux P; Bouscary D; Recher C; Bardet V
    Haematologica; 2011 Dec; 96(12):1792-8. PubMed ID: 21933861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients.
    Almohsen F; Al-Mudallal SS
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(2):145-151. PubMed ID: 31438833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leukemic Stem Cell (CD34
    Mohamed MMI; Aref S; Agdar MA; Mabed M; El-Sokkary AMA
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):508-513. PubMed ID: 33931379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.